Volume 189 - Issue 3
Probiotics: sorting the evidence from the myths
Authors: Mimi Pham, Daniel A Lemberg and Andrew S Day
Med J Aust 2008; 189 (3): 182-183. || doi: 10.5694/j.1326-5377.2008.tb01971.x
Published online: 4 August 2008
Published online: 4 August 2008
In reply: The comments by Chatterjee and Fraser regarding the danger of administering probiotics to patients with acute severe illnesses are important additions to the debate on the risks and benefits of probiotic administration. We also thank Senanayake for his interesting comments on the possible role of probiotics in weight gain.
The recently published multicentre trial1 describing unexpected adverse events associated with probiotics in acutely unwell patients with severe pancreatitis is one example of an adverse outcome following probiotic administration. The use of probiotics in patients with severe comorbidities and in those who are immunocompromised is also contraindicated. There are reported cases of Lactobacillus GG sepsis in premature babies with short gut syndrome,2 and Saccharomyces boulardii fungaemia has been described in immunocompromised patients.3
It is interesting to note that two systematic reviews have assessed the efficacy of probiotics in prevention of necrotising enterocolitis in premature (< 33 weeks’ gestation) and very low birthweight (< 1500 g) infants.4,5 Both reviews concluded that probiotics may decrease the incidence of necrotising enterocolitis in preterm infants, and that severe adverse events were not associated with probiotics in these unwell and immunodeficient patients. However, there were insufficient data to comment definitively on the short-term or long-term safety of probiotics in these infants; this will require assessment in future large trials.
The increased scrutiny of probiotics resulting from the publication of the adverse outcomes in adults with severe acute pancreatitis1 may, by necessity, slow the commencement and progression of these larger trials in infants in the neonatal intensive care setting.
References
- Besselink MGH, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-659. 0_CBBHDJJA
- Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004; 38: 457-458. 0_CBBIDBCB
- Riquelme AJ, Calvo MA, Guzmán AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36: 41-43. 0_CBBHDAJD
- Barclay AR, Stenson B, Simpson JH, et al. Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol Nutr 2007; 45: 569-576. 0_CBBCGGDA
- Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007; 369: 1614-1620. 0_i1091848
Country revealing the way: evaluating Elder‐governed cultural therapy for Aboriginal and Torres Strait Islander young people with mental health conditions
Alasdair Vance, Janet McGaw, Jo Winther, Naomi Tootell, Herb Patten, Sandra Eades
No silver lining with health misinformation: argyria caused by intentional silver consumption
Luke Collins, Logesh Palanikumar, Stephen Bacchi
Hyperkalaemic cardiac arrest due to cream of tartar ingestion
Daniel Yee Lee Ng, Laksmi Govindasamy, Andrew Hughes, Hwee Min Lee
From talk to action: Indigenous Reference Groups drive practice change in kidney transplantation care
Kelli J Owen, Katie Cundale, Jaquelyne T Hughes, Stephen P McDonald, Matilda D'Antoine, Shilpanjali Jesudason
The not‐so‐natural herb: a case of exogenous Cushing syndrome
Yi‐An Pan, David Roberts, Yi‐An Pan, David Roberts
Lead poisoning outbreak from consumption of contaminated Ayurvedic medication
Mark J Ferson, Sinead Flanigan, Toni Cains